KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Depreciation & Amortization (2016 - 2025)

CRISPR Therapeutics AG's Accumulated Depreciation & Amortization history spans 11 years, with the latest figure at $91.1 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 25.99% year-over-year to $91.1 million; the TTM value through Dec 2025 reached $91.1 million, up 25.99%, while the annual FY2025 figure was $91.1 million, 25.99% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $91.1 million at CRISPR Therapeutics AG, up from $72.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $91.1 million in Q4 2025 and bottomed at $23.9 million in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $46.2 million (2022), against an average of $49.2 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization soared 85.67% in 2022 before it dropped 11.32% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $37.8 million in 2021, then fell by 10.51% to $33.8 million in 2022, then surged by 57.94% to $53.4 million in 2023, then skyrocketed by 35.26% to $72.3 million in 2024, then increased by 25.99% to $91.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Accumulated Depreciation & Amortization are $91.1 million (Q4 2025), $72.3 million (Q4 2024), and $67.8 million (Q3 2024).